STOCK TITAN

UNITY Biotechnology to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.

Citi 17th Annual BioPharma Conference
Format: One-on-one investor meetings
Date: September 6 – 8, 2022
Location: Four Seasons Hotel Boston, Massachusetts

H.C. Wainwright 24th Annual Global Investment Conference
Format: Corporate update presentation and one-on-one investor meetings
Date and Time: Monday, September 12, 2022 at 4 PM ET
Location: Virtual

A live webcast of the H.C. Wainwright presentation is available by clicking here and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.

About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact:
Evoke Canale
Jason Spark
Jason.spark@evokegroup.com

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Source: Unity Biotechnology, Inc


Unity Biotechnology Inc

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
US
Brisbane

About UBX

unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.